Vermillion Announces Return of Eric Fung, M... ( FREMONT Calif. Oct. 2 /- Vermillion I...)

Vermillion Announces Return of Eric Fung, M.D., Ph.D.

Date:10/2/2009

FREMONT, Calif., Oct. 2 /PRNewswire-FirstCall/ -- Vermillion, Inc (OTC: VRMLQ.PK) today announced that Eric Fung, M.D., Ph.D., has rejoined the company to become its Chief Science Officer. This position will be formally held by Dr. Fung upon the completion of the Company's restructuring and reorganization under Chapter 11 of the U.S. Bankruptcy Code or earlier, if deemed appropriate by Vermillion's Board of Directors. In the interim, Dr. Fung will work as an independent consultant.

"Dr. Fung was instrumental in the development of the OVA1(TM) test, including biomarker discovery to validation, design and execution of the clinical trial, and submission to the FDA," said Gail Page, Executive Director of the Company. "We are pleased to welcome him back to Vermillion, where he will play a key role in commercialization of the OVA1 test as well as further development of other potential tests in Vermillion's pipeline."

Dr. Fung, age 39, is returning to the company after serving as Director of Clinical Research at Roche Molecular Systems. At Roche, he helped oversee a cervical cancer screening clinical trial involving 45,000 women. Dr. Fung originally joined Vermillion in May 2000 as a lead scientist in the newly formed Biomarker Discovery Centers. He was promoted to Vice President and Chief Scientific Officer in June 2006.

Prior to joining Vermillion, Dr. Fung was a Howard Hughes sponsored researcher at Stanford University. Dr. Fung has anatomic pathology training from Stanford Medical School and obtained his M.D. and Ph.D. degrees from the Johns Hopkins University School of Medicine. He graduated with a B.S. with honors from the California Institute of Technology. Dr. Fung has also held an Adjunct Assistant Professor position in the Department of Pathology at the Johns Hopkins University School of Medicine.

About the OVA1 Test

The OVA1 Test is a qualitative serum test that combines the results of f
'/>"/>

SOURCE Vermillion, Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3
Related biology technology :

1. Vermillion (Formerly Ciphergen) Announces $20.5 Million Private Placement of Common Stock
2. Vermillion and Collaborators Discover Protein Biomarker Associated with Peripheral Artery Disease
3. Vermillion, Inc. Announces Receipt Of Notice Of Compliance From Nasdaq
4. Vermillion to Webcast Presentation at the Acumen BioFin 9th Annual Healthcare Conference, November 5-7, New York
5. Vermillion and Johns Hopkins Sign Collaborative Research and License Agreements to Develop Molecular Diagnostic Tests
6. Vermillion Receives NASDAQ Notice of Non-Compliance
7. Vermillion and Stanford University Sign Exclusive License Agreement for Novel Biomarker Panel to Assess Peripheral Artery Disease Risk
8. Vermillion Announces Effectiveness of Reverse Stock Split
9. Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones
10. Vermillion Meets Minimum Bid Price and Receives NASDAQ Staff Determination Letter for Minimum Market Capitalization
11. Vermillion Biomarker Panel Potential Aid in the Diagnosis of Peripheral Artery Disease

Post Your Comments:

(Date:12/11/2009)... miRagen Therapeutics, Inc., a biopharmaceutical company focused on ... for cardiovascular and muscle disease, today announced the ... a crucial role in the progression of amyotrophic ... in neuromuscular synaptic regeneration in mice. The ... the journal Science , reveal miR-206 as ...

(Date:12/11/2009)... (12/11/2009) Boston College researchers have observed the "hot ... time and successfully harvested the elusive charges using ultra-thin ... power efficiency, the authors report in the current online ... light is captured in solar cells, it generates free ... order to snare these charges, the electrons must reach ...

(Date:12/11/2009)... Algeta ASA (OSE: ALGETA), the,cancer therapeutics company, ... the,US, the Tulane Cancer Center, New Orleans, ... clinical study of Alpharadin in men with,castration-resistant ... has metastasized to the skeleton. , ... SYMptomatic Prostate CAncer) study is a,double-blind, randomized, ...

(Date:12/11/2009)... CAMBRIDGE, Mass., Dec. 11 Gwathmey, ... company specializing in cancer, staph aureus, and cardiovascular ... Pre-clinical Services announced today that Rosalie Dunn, Ph.D., ... Dr. Dunn has over 28 years of experience ... Prior to joining Gwathmey, Dr. Dunn managed ...

Breaking Biology Technology:miRagen announces discovery of key microRNA implicated in Lou Gehrig's disease 2 Elusive 'hot' electrons captured in ultra-thin solar cells 2 Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 2 Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 3 Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 4 Rosalie Dunn, Ph.D., Joins Gwathmey, Inc. as Chief Executive Officer 2

[0] miRagen announces discovery of key microRNA implicated in Lou Gehrig's disease [0] Elusive 'hot' electrons captured in ultra-thin solar cells [0] Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans [0] Rosalie Dunn, Ph.D., Joins Gwathmey, Inc. as Chief Executive Officer

... China Technology,Development Group Corporation (Nasdaq: CTDC; "the Company" ... products and solutions focusing on,solar energy business in ... ceremony to showcase the first SnO2 production line ... 2007., Accompanied by Mr. Alan Li, our ...

... 3 Neogen Corporation,(Nasdaq: NEOG ) announced today ... 2008, which ended Nov. 30, increased 34% from the ... net income in the,quarter rose to $0.22 per share, ... income of $3,254,000 set another quarterly,record for the 25-year-old ...

... a cancer therapeutics,company, announced today the appointment of ... of Directors. Mr. Clarke is a senior biotechnology ... over a,30-year industry career., "It is a ... of our Board,of Directors," said Julie A. Olson, ...

Other Biology Technology:CTDC Holds a Ribbon Cutting Ceremony to Showcase First SnO2 Production Line 2 CTDC Holds a Ribbon Cutting Ceremony to Showcase First SnO2 Production Line 3 Neogen Reports 34% Increase in Net Income, 23% Increase in Revenues 2 Neogen Reports 34% Increase in Net Income, 23% Increase in Revenues 3 Neogen Reports 34% Increase in Net Income, 23% Increase in Revenues 4 Neogen Reports 34% Increase in Net Income, 23% Increase in Revenues 5 Mersana Therapeutics Appoints C. Boyd Clarke Chairman of the Board of Directors 2

CTDC Holds a Ribbon Cutting Ceremony to Showcase First SnO2 Production Line Neogen Reports 34% Increase in Net Income, 23% Increase in Revenues Mersana Therapeutics Appoints C. Boyd Clarke Chairman of the Board of Directors

(Date:12/15/2009)... a team of Spanish and American researchers found the fossil ... Huelva. Now they have published, for the first time, the ... the death of the young cetacean, possibly a baleen whale ... discovery of the partial fossil remains of a whale from ... Sands sedimentary formation, but it is the first time that ...

(Date:12/15/2009)... future, consumers can look forward to ultra-low powered ... PDAs and mobile phones. This is made possible ... which are critical elements for power optimisation and ... , Analog IC design is the key enabling ... pre-position the nation in advanced analog and mixed ...

(Date:12/15/2009)... laboratory model organism, but there are currently few ... and blood-forming tissues in this species. A ... resources from Cold Spring Harbor Laboratory Press fills ... step-by-step protocols for the preparation, enumeration, and microscopic ... hematopoietic tissues in the mouse. The laboratory ...

[0] Story of 4.5 million-year-old whale unveiled in Huelva [0] NTU and EDB launch S$50 million ($36 million) integrated circuit design research center [0] New source of classical techniques for blood-based studies in the laboratory mouse

... Yale scientists have created nanowire sensors coupled with simple ... to be used for point-of-care (POC) disease detection, according ... The sensors use activation of immune cells by highly ... cells as the detector. When T cells are ...

... may make us all go a little gooey, but it,s ... researchers at The Australian National University. , The study ... ANU suggests that despite fears mothers may have that ... suggest that is true. The findings have been released as ...

... Aware, Inc. (Nasdaq:,AWRE), a leading supplier of broadband technology ... the company,s operating results,for the third quarter of 2008 ... CEO Michael Tzannes and CFO Rick Moberg will host ... by Thomson and can be accessed on the,Investor Relations ...

Other Biology News:Sensitive nanowire disease detectors made by Yale scientists 2 Pregnancy not turning minds to mush: Study 2 Aware Announces Q3 2008 Earnings Conference Call 2

Sensitive nanowire disease detectors made by Yale scientists Pregnancy not turning minds to mush: Study Aware Announces Q3 2008 Earnings Conference Call

... The 820-MS features Varians unique ... provides simple, routine removal of troublesome ... more flexible interference-free analysis without the ... quadrupole ion guides, or cells. And, ...

a1-Antitrypsin (human, alpha-1 AT)...

... are used to study co-translational and ... events such as signal peptide cleavage, ... can be examined by the translation ... in the presence of these microsomal ...

... Bio luciferase assay. Mo Bio Laboratories offers the ... you to certify your products ATP-Free with a ... deliver them to your customers in a timely ... 3.5 x 10-12 /l, which will allow you ...

Biology Products:

Varian 820-MS from Varian, Inc.Mouse Anti-Human a1-Antitrypsin (alpha-1 AT) Monoclonal Antibody, Unconjugated, Clone 4E5 from AntibodyShop A/S Canine Pancreatic Microsomal Membranes from Promega ATP contamination testing from Mo Bio Laboratories, Inc.

Vermillion Announces Return of Eric Fung, M...( FREMONT Calif. Oct. 2 /- Vermillion I...)